# CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

> **NCT00658437** · PHASE2 · COMPLETED · sponsor: **Cytavis Biopharma GmbH** · enrollment: 31 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** CY-503

## Key facts

- **NCT ID:** NCT00658437
- **Lead sponsor:** Cytavis Biopharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-08
- **Final completion:** 2010-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658437, "CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00658437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*